Genomenon is an AI-driven genomics company that organizes the world's genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.
Genomenon's mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer.
Genomenon was founded in 2014 by Mark J. Kiel, Steve Schwartz, Kojo Elenitoba-Johnson and Megan Lim. The company is headquartered in Ann Arbor, Michigan.
Genomenon leverages AI (Artificial Intelligence) to organize the world's genomic knowledge and put it at the fingertips of doctors and clinicians to diagnose patients with rare and genetic disease and cancer, and researchers to help create precision medicine targeted at molecular drivers of disease.
Genomenon's Mastermind Genomic Search Engine is used by more than 1,000 genetic testing labs and hospitals worldwide to provide clinical insight into the scientific literature on genomic data.
Genomenon's Prodigy Genomic Landscapes are used by top Pharma and biopharma companies to gain a profound understanding of the genetic drivers and clinical attributes of any genetic disease, from rare diseases to cancer.
Genomenon is backed by National Institutes of Health, Beringea, Spring Mountain Capital, BroadOak Capital Partners, Riverine Ventures, Green Park & Golf Ventures, the University of Michigan, Michigan Angel Fund, Invest Detroit, InvestMichigan, and others. The company raised $20M in Series B round on Mar 10, 2022. This brings Genomenon's total funding to $32.8M to date.